SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors 24-month HOPE-3 extension data for deramiocel, including a reported 76% slowing of upper-limb decline after placebo patients switched to treatment, is driving attention and a sharp bullish reaction. Traders are debating whether the open-label results strengthen the case for FDA approval ahead of the November decision, while some question whether they resolve the agencys earlier statistical concerns; short-squeeze talk is also prominent.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

A DEA administrative judge paused the broader cannabis rescheduling case while considering whether to add a government watchdog report on agency procedures, delaying a recommendation on moving adult-use cannabis to Schedule III. Traders are divided between viewing the pause as a temporary procedural delay and fearing a longer setback, with some treating the selloff as a buying opportunity; the pause does not reverse the earlier medical-cannabis rescheduling action.

Six Flags Entertainment Corp. engages in operating amusement parks in North America. It operates amusement parks, water parks, and resorts. The company is headquartered in Charlotte, NC.

Six Flags Entertainment Corp.

Six Flags Entertainment Corp

Activist investor Jana Partners demand that Six Flags explore a sale is driving discussion, against a backdrop of disappointing results, heavy debt and a sharp share-price decline. Traders are split: some see a strategic review as a way to unlock value, while others worry it could distract management from improving operations and paying down debt.

Enphase Energy, Inc. is a global energy technology company, which engages in the business of designing, developing, manufacturing, and selling home energy solutions that manage energy generation, energy storage, control, and communications on one intelligent platform. It operates through the following geographical segments: the United States, the Netherlands, and Others. The company was founded by Raghuveer R. Belur and Martin Fornage in March 2006 and is headquartered in Fremont, CA.

Enphase Energy Inc

Enphases IQ Solid State Transformer push into AI data-center power is drawing attention, with traders focused on U.S. production progress and planned demonstrations and customer pilots. Bulls see a potential growth catalyst and short-squeeze setup, while skeptics point to the long commercialization timeline, interest-rate sensitivity, and weak residential-solar demand.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Positive Phase 3 results for Vandas Hetlioz in delayed sleep-wake phase disorder are driving attention; the company plans to discuss the data with the FDA and seek a supplemental indication. Traders are largely upbeat about the potential expansion, while some question its commercial impact and whether the stock can hold its gains; FDA approval remains pending.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances raised full-year revenue outlook, citing stronger demand for Amtagvi and Proleukin, drove a sharp rally. Traders largely celebrated the improved commercial outlook and speculated about short covering, while others warned of a pullback or dilution and looked ahead to lung-cancer data.

Armada Acquisition Corp. II is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combinations with one or more businesses. The company was founded on October 3, 2024 and is headquartered in Miami, FL.

Armada Acquisition Corp. II - Ordinary Shares- Class A

Evernorth Holdings Inc.

Evernorths transition from the Armada SPAC to Nasdaq trading as XRPN, alongside its XRP-treasury strategy, is driving attention; traders see the shares and warrants as leveraged exposure to XRP. Bullish hopes for the treasury and warrant upside are balanced by questions about valuation, redemptions, merger execution, and volatility.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

A SAM.gov listing has prompted debate over whether Red Cat has a modest Black Widow-related opportunity, while traders question the lack of confirmed large orders and promised contract updates. The conversation is predominantly bearish, with concerns about weak sales, management credibility and the companys performance in Pentagon drone competitions, though some remain optimistic about future defense demand.

T-Mobile US, Inc. engages in the provision of wireless communications services under the T-Mobile and MetroPCS brands. It offers postpaid and prepaid wireless voice, messaging and data services, and wholesale wireless services. The company was founded in 1994 and is headquartered in Bellevue, WA.

T-Mobile US Inc

Barclays cautious pre-Q3 outlook, citing limited earnings upside and emerging competition from Starlink, is feeding concern around T-Mobiles decline. Traders are split between viewing the selloff and fresh lows as an overreaction and expecting further weakness amid competitive and growth concerns.

VS Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

Traders are positioning in UVIX as a leveraged volatility hedge, anticipating a VIX spike amid concerns about rates, oil, geopolitical risks and a potential market pullback. The debate centers on that speculative upside versus persistent losses from contango and daily decay, with many saying UVIX has failed to track market weakness as expected.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$ENTA Seems pretty random to be cutting staff now...perhaps, once Clinical Trials are well underway they just turn to more specialized contract staffing? Unrelated (probably) but should be getting word on the EU lawsuit with $PFE soon enough . 

https://www.fiercebiotech.com/biotech/enanta-sheds-staffers-key-antiviral-and-immunology-readouts-loom

As antiviral specialist Enanta Pharmaceuticals endeavors to expand into immunology, the company has decided to lay off 37 employees, Fierce has learned. | As antiviral specialist Enanta Pharmaceuticals endeavors to expand into immunology, the company has decided to lay off 37 employees, Fierce has learned.

Fierce Biotech

Enanta sheds staffers as key antiviral, immunology readouts loom

StockTwits For Android 

Enanta Pharmaceuticals Inc

Pfizer Inc

 Seems pretty random to be cutting staff now...perhaps, once Clinical Trials are well underway they just turn to more specialized contract staffing? Unrelated (probably) but should be getting word on the EU lawsuit with 

Dy2ski

@Dy2ski Am I missing something? 
“The U.S. Court of Appeals for the Federal Circuit ruled in June 2026 that Enanta Pharmaceuticals&#39; key patent used in its infringement lawsuit against Pfizer&#39;s COVID-19 antiviral drug Paxlovid is invalid“

StockTwits for iOS

 Am I missing something? 
“The U.S. Court of Appeals for the Federal Circuit ruled in June 2026 that Enanta Pharmaceuticals' key patent used in its infringement lawsuit against Pfizer's COVID-19 antiviral drug Paxlovid is invalid“

ApiL

@Dy2ski “This U.S. invalidation outcome creates a substantial hurdle for Enanta&#39;s parallel enforcement strategies, though the UPC proceedings in Europe run under separate regional jurisdiction and patent validity standards.”

 “This U.S. invalidation outcome creates a substantial hurdle for Enanta's parallel enforcement strategies, though the UPC proceedings in Europe run under separate regional jurisdiction and patent validity standards.”